SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 3-DIMENSIONAL PHARMACEUTICALS (DDDP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (75)5/31/2002 10:31:03 AM
From: keokalani'nui  Read Replies (1) of 146
 
All I can tell so far is that crgn's claims appear to involve peptide/protein antagonists and DDDP is working with smallmol; the discovery of MDM2's p53 suppressive effects (especially the work from Dublin) predates crgn's earliest claims; and 3DP has no issued patents on MDM2 (including HDM2). I never have enough time and certainly have not enough training to look at patent issues such as this, so.....

Wilder
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News